Key result
GLP-1 and liraglutide induce the expression and secretion of FNDC5 derivatives, including a novel secretable isoform (sFNDC5), which stimulates lipolysis and exhibits anti-obesity activities.
Why the study?
Does GLP-1 induce lipolysis and anti-obesity effects via FNDC5 derivatives in β cells and obese mouse models?
Population
Wild type and FNDC5-knockout β cells, mouse pancreas and brain tissues, rat tissues, and an obese mouse model
Comparison
GLP-1, liraglutide, and recombinant sFNDC5 vs Untreated controls and FNDC5-knockout models
Design
Preclinical
Authors
Loading...
Does not support changing GLP-1 prescribing; leaves open sFNDC5's role in clinical weight loss.
Does GLP-1 induce lipolysis and anti-obesity effects via FNDC5 derivatives in β cells and obese mouse models?
GLP-1 exerts anti-obesity effects by inducing the secretion of FNDC5 derivatives, including a novel secretable isoform (sFNDC5), which mediates lipolysis and adipocyte browning.
Li et al. (2021) studied Obesity and Type 2 Diabetes. GLP-1 / Liraglutide / Recombinant sFNDC5 was evaluated on Lipolysis and FNDC5 expression. GLP-1 and liraglutide induce the expression and secretion of FNDC5 derivatives, including a novel secretable isoform (sFNDC5), which stimulates lipolysis and exhibits anti-obesity activities.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: